AbbVie to Acquire Capstan Therapeutics for $2.1 Billion to Advance In Vivo CAR-T Therapy for Autoimmune Diseases

—The application for various awards has started successively, stay tuned—

6Month30Day, AbbVie announced the acquisition based onmRNA-tLNPTechnical Route Development In VivoCAR-TTheStar CompanyCapstan Therapeutics, Acquisition includes potentialfirst-in-classIn Vivo AntibodyCD19 CAR-TProjectCPTX2309。CPTX2309Currently inIPhase clinical, used for treatmentBCell-mediated autoimmune diseases. In addition, AbbVie will also obtainCapstanProprietarytLNPPlatform technology, a platform capable of deliveringmRNASuch as effective payloads, thereby engineering specific cell types in vivo. According to the terms of the agreement, AbbVie will pay up to21Billion US dollarsCash。

In vivoCAR-TRepresents a potential new therapeutic approach in medicine, with the prospect of bringing transformative changes to the field of cell therapy, particularly revolutionizing the treatment of autoimmune diseases.CPTX2309Is born fromCapstanPipeline of proprietary technology platform, targetingLNPDelivery Encoding AntiCD19 CARThemRNAToCD8 TIn cells.

CapstanCurrently being conducted in healthy volunteers in AustraliaCPTX2309Treating Autoimmune DiseasesIPhase Trial.6Month11The other day, the company announced,CPTX2309TheICompletion of the first batch of subject dosing in the Phase trial.

In addition,6Month19Day,CapstanIn collaboration with the University of PennsylvaniaPerelmanThe research team at the Medical CollegeScienceThe journal published a breakthrough achievement, detailing the basis ofCD8TargetedLNPDelivery of Anti-CD19 CAR mRNAIn the bodyCAR-TStrategy. From rodents and non-human primates (NHP) The data from the model shows that in vivoCAR-TThe technology demonstrated excellent anti-tumor efficacy; additionally, in autoimmune models, it was observedBDeep clearance of cells and led to "immune reset".

Over the past year, in the bodyCAR-TThe track is hot. Previously, based onLentiviral VectorIn vivo platformCAR-TThe company has been awarded by multipleMNCThe favor, such as2024Year1Month,AbbVieAnnounce withUmojaFor the development of in vivo (in situ)CAR-TTotal Potential Therapy14.4USD billion collaboration; In the same year2Month,AstellasAnnounce withKeloniaReach cooperation to develop in vivoCAR-T, with a potential total transaction value exceeding8.75Yimei;11Month,Novartis"Join Hands"Vyriad, Development in vivoCAR-TTherapy.2025Year3Month,AstraZenecaAnnounced with10Billion-dollar acquisition in vivoCAR-TCompanyEsoBiotech, pushing the track's popularity to new heights.

This time, AbbVie has launched based onmRNA-tLNPIn vivo technical routeCAR-TThe first large acquisition, and it was after the company had alreadyUmojaIn Vivo Viral VectorCAR-TOn the basis of reaching cooperation, it is evident thatmRNA-tLNPThe optimistic outlook on the technological route. Will this major acquisition initiate the in vivo application of this technological route?CAR-TThe surge in transactions deserves further attention.

References:

https://www.capstantx.com/press-releases/abbvie-to-acquire-capstan-therapeutics-further-strengthening-commitment-to-transforming-patient-care-in-immunology/

PharmaCube Pro

Insight into Global Biomedical Frontiers Trends

Empowering the Transformation of China's Indigenous Innovation Achievements

Media Cooperation: 15895423126